Susan H Eshleman
Overview
Explore the profile of Susan H Eshleman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
230
Citations
9978
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skalland T, de Dieu Tapsoba J, Zangeneh S, Floyd S, Ayles H, Bock P, et al.
AIDS Res Ther
. 2025 Mar;
22(1):30.
PMID: 40055795
Introduction: HPTN 071 (PopART) implemented a comprehensive HIV prevention package which aimed to reduce HIV incidence within 21 communities of Zambia and South Africa: Arm A, PopART intervention of universal...
2.
Fogel J, Persaud D, Piwowar-Manning E, Richardson P, Szewczyk J, Marzinke M, et al.
AIDS Res Hum Retroviruses
. 2024 Oct;
41(1):30-36.
PMID: 39466048
We evaluated HIV DNA levels in individuals who received long-acting cabotegravir (CAB-LA) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) pre-exposure prophylaxis in the HPTN 083 and 084 trials and had HIV DNA...
3.
Grant-McAuley W, Morgenlander W, Ruczinski I, Kammers K, Laeyendecker O, Hudelson S, et al.
PLoS One
. 2024 Sep;
19(9):e0305976.
PMID: 39288118
Background: High HIV viral loads (VL) are associated with increased morbidity, mortality, and on-going transmission. HIV controllers maintain low VLs in the absence of antiretroviral therapy (ART). We previously used...
4.
Landovitz R, Delany-Moretlwe S, Fogel J, Marzinke M, Piwowar-Manning E, Richardson P, et al.
N Engl J Med
. 2024 Jul;
391(13):1253-1256.
PMID: 39046350
No abstract available.
5.
Fogel J, Piwowar-Manning E, Moser A, Hill T, Ahmed S, Cummings V, et al.
Microbiol Spectr
. 2024 Jul;
:e0030724.
PMID: 38980027
Importance: HIV RNA assays can detect HIV infections earlier than HIV rapid tests or Ag/Ab tests in persons using CAB-LA PrEP. Earlier HIV diagnosis could allow for earlier treatment initiation...
6.
Moore H, Palumbo P, Notarte K, Fogel J, Cummings V, Gamble T, et al.
J Clin Microbiol
. 2024 May;
62(6):e0013624.
PMID: 38727213
HIV genotyping is used to assess HIV susceptibility to antiretroviral drugs. The Applied Biosystems HIV-1 Genotyping Kit with Integrase (AB kit, Thermo Fisher Scientific) detects resistance-associated mutations (RAMs) in HIV...
7.
Hall M, Golubchik T, Bonsall D, Abeler-Dorner L, Limbada M, Kosloff B, et al.
Lancet Microbe
. 2023 Dec;
5(1):e62-e71.
PMID: 38081203
Background: In the last decade, universally available antiretroviral therapy (ART) has led to greatly improved health and survival of people living with HIV in sub-Saharan Africa, but new infections continue...
8.
Landovitz R, Hanscom B, Clement M, Tran H, Kallas E, Magnus M, et al.
Lancet HIV
. 2023 Nov;
10(12):e767-e778.
PMID: 37952550
Background: Injectable cabotegravir was superior to daily oral tenofovir disoproxil fumarate plus emtricitabine for HIV prevention in two clinical trials. Both trials had the primary aim of establishing the HIV...
9.
Grant-McAuley W, Piwowar-Manning E, Clarke W, Breaud A, Zewdie K, Moore A, et al.
J Int AIDS Soc
. 2023 Oct;
26(10):e26179.
PMID: 37886843
Introduction: HIV controllers have low viral loads (VL) without antiretroviral treatment (ART). We evaluated viraemic control in a community-randomized trial conducted in Zambia and South Africa that evaluated the impact...
10.
Marzinke M, Hanscom B, Wang Z, Safren S, Psaros C, Donnell D, et al.
Lancet HIV
. 2023 Oct;
10(11):e703-e712.
PMID: 37783219
Background: The HIV Prevention Trials Network (HPTN) 083 trial showed that long-acting injectable cabotegravir was more effective than tenofovir disoproxil fumarate plus emtricitabine in preventing HIV in cisgender men and...